Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer

Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study

Clinics ◽

10.6061/clinics/2021/e2251 ◽

2021 ◽

Vol 76 ◽

Author(s):

Yan Lan ◽

Shuo Zhou ◽

Weihong Feng ◽

Ying Qiao ◽

Xueming Du ◽

...

Keyword(s):

Lung Cancer ◽

Retrospective Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Tumor Mutation Burden ◽

Mutation Burden ◽

Epidermal Growth ◽

Anisomycin sensitizes non‐small‐cell lung cancer cells to chemotherapeutic agents and epidermal growth factor receptor inhibitor via suppressing PI3K/Akt/mTOR

Fundamental and Clinical Pharmacology ◽

10.1111/fcp.12641 ◽

2020 ◽

Author(s):

Hongxia Tan ◽

Biao Hu ◽

Fan Xie ◽

Chuanbing Zhu ◽

Zhenshun Cheng

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Chemotherapeutic Agents ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz268.089 ◽

2019 ◽

Vol 30 ◽

pp. v789

Author(s):

H.-P. Hsieh ◽

J.-Y. Chang ◽

C.-T. Yeh ◽

S.-Y. Lin ◽

Y.-Y. Ke ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Clinical Candidate ◽

Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2012.12.001 ◽

2013 ◽

Vol 14 (4) ◽

pp. 322-332 ◽

Cited By ~ 58

Author(s):

Shirish M. Gadgeel ◽

Antoinette Wozniak

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Small Cell Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-07-0567 ◽

2008 ◽

Vol 7 (3) ◽

pp. 599-606 ◽

Cited By ~ 48

Author(s):

Takafumi Okabe ◽

Isamu Okamoto ◽

Sayaka Tsukioka ◽

Junji Uchida ◽

Tsutomu Iwasa ◽

...

Keyword(s):

Lung Cancer ◽

Thymidylate Synthase ◽

Antitumor Effect ◽

Growth Factor Receptor ◽

Small Cell ◽

Lung Cancer Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Oncogene ◽

10.1038/onc.2015.142 ◽

2015 ◽

Vol 35 (7) ◽

pp. 878-886 ◽

Cited By ~ 46

Author(s):

K Yonesaka ◽

K Hirotani ◽

H Kawakami ◽

M Takeda ◽

H Kaneda ◽

...

Keyword(s):

Lung Cancer ◽

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Phase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.14605 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 14605-14605 ◽

Cited By ~ 2

Author(s):

A. A. Chiappori ◽

T. Tanvetyanon ◽

C. A. Williams ◽

S. Antonia ◽

S. Litschauer ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Phase I Trial ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2016.11.006 ◽

2017 ◽

Vol 18 (3) ◽

pp. 281-285 ◽

Cited By ~ 14

Author(s):

Matthew S. Lara ◽

William S. Holland ◽

Danielle Chinn ◽

Rebekah A. Burich ◽

Primo N. Lara ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Preclinical Evaluation ◽

Epidermal Growth ◽

Met Inhibitor ◽

Abstract 4789: Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer

10.1158/1538-7445.am2018-4789 ◽

2018 ◽

Author(s):

Hsing-Pang Hsieh ◽

Jang-Yang Chang ◽

Ching-Chuan Kuo ◽

John Hsu

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Promising Treatment ◽

Clinical Candidate ◽

Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells

PLoS ONE ◽

10.1371/journal.pone.0069104 ◽

2013 ◽

Vol 8 (7) ◽

pp. e69104 ◽

Cited By ~ 27

Author(s):

Shi-Jiang Fei ◽

Xu-Chao Zhang ◽

Song Dong ◽

Hua Cheng ◽

Yi-Fang Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Inhibitor Resistance